154 related articles for article (PubMed ID: 31332268)
21. 5-formylcytosine and 5-hydroxymethyluracil as surrogate markers of TET2 and SF3B1 mutations in myelodysplastic syndrome, respectively.
Gackowski D; Gawronski M; Kerr C; Radivoyevitch T; Zarakowska E; Starczak M; Abakir A; Ruzov A; Maciejewski JP; Olinski R
Haematologica; 2020 May; 105(5):e213-e215. PubMed ID: 31488558
[No Abstract] [Full Text] [Related]
22. [Molecular mechanisms underlying leukemic transformation of myelodysplastic syndromes (MDS) and chronic myelogenous leukemia (CML)].
Kitamura T; Watanabe-Okochi N; Inoue D; Togami K; Uchida T; Kagiyama Y; Kawabata K; Chiba S; Harada Y; Harada H; Kitaura J; Nakahara F
Rinsho Ketsueki; 2012 Aug; 53(8):734-9. PubMed ID: 22975812
[No Abstract] [Full Text] [Related]
23. [Recent advances of molecular mechanisms influencing prognosis of myelodysplastic syndrome - review].
Guo J; Chang CK; Li X
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Aug; 20(4):1020-4. PubMed ID: 22931676
[TBL] [Abstract][Full Text] [Related]
24. Driver somatic mutations identify distinct disease entities within myeloid neoplasms with myelodysplasia.
Malcovati L; Papaemmanuil E; Ambaglio I; Elena C; Gallì A; Della Porta MG; Travaglino E; Pietra D; Pascutto C; Ubezio M; Bono E; Da Vià MC; Brisci A; Bruno F; Cremonesi L; Ferrari M; Boveri E; Invernizzi R; Campbell PJ; Cazzola M
Blood; 2014 Aug; 124(9):1513-21. PubMed ID: 24970933
[TBL] [Abstract][Full Text] [Related]
25. Using PU.1 and Jun dimerization protein 2 transcription factor expression in myelodysplastic syndromes to predict treatment response and leukaemia transformation.
Boasman K; Simmonds MJ; Graham C; Saunthararajah Y; Rinaldi CR
Ann Hematol; 2019 Jun; 98(6):1529-1531. PubMed ID: 30721335
[No Abstract] [Full Text] [Related]
26. Epigenetic landscape correlates with genetic subtype but does not predict outcome in childhood acute lymphoblastic leukemia.
Gabriel AS; Lafta FM; Schwalbe EC; Nakjang S; Cockell SJ; Iliasova A; Enshaei A; Schwab C; Rand V; Clifford SC; Kinsey SE; Mitchell CD; Vora A; Harrison CJ; Moorman AV; Strathdee G
Epigenetics; 2015; 10(8):717-26. PubMed ID: 26237075
[TBL] [Abstract][Full Text] [Related]
27. Biological Activities of RUNX1 Mutants Predict Secondary Acute Leukemia Transformation from Chronic Myelomonocytic Leukemia and Myelodysplastic Syndromes.
Tsai SC; Shih LY; Liang ST; Huang YJ; Kuo MC; Huang CF; Shih YS; Lin TH; Chiu MC; Liang DC
Clin Cancer Res; 2015 Aug; 21(15):3541-51. PubMed ID: 25840971
[TBL] [Abstract][Full Text] [Related]
28. Mutation of ten-eleven translocation-2 is associated with increased risk of autoimmune disease in patients with myelodysplastic syndrome.
Oh YJ; Shin DY; Hwang SM; Kim SM; Im K; Park HS; Kim JA; Song YW; Márquez A; Martín J; Lee DS; Park JK
Korean J Intern Med; 2020 Mar; 35(2):457-464. PubMed ID: 31640337
[TBL] [Abstract][Full Text] [Related]
29. Acute myeloid leukaemia: recent data on prognostic gene mutations, in relation to stratified therapies for elderly patients.
Soura EN; Karikas GA
J BUON; 2019; 24(4):1326-1339. PubMed ID: 31646775
[TBL] [Abstract][Full Text] [Related]
30. Methylation of the CpG island near SOX7 gene promoter is correlated with the poor prognosis of patients with myelodysplastic syndrome.
Fan R; Zhang LY; Wang H; Yang B; Han T; Zhao XL; Wang W; Wang XQ; Lin GW
Tohoku J Exp Med; 2012 Jun; 227(2):119-28. PubMed ID: 22706399
[TBL] [Abstract][Full Text] [Related]
31. Concurrent mutations in other epigenetic modulators portend better prognosis in BCOR-mutated myelodysplastic syndrome.
Badaat I; Mirza S; Padron E; Sallman D; Komrokji R; Song J; Hussaini MO
J Clin Pathol; 2020 Apr; 73(4):209-212. PubMed ID: 31771970
[TBL] [Abstract][Full Text] [Related]
32. Aberrant epigenetic and genetic marks are seen in myelodysplastic leukocytes and reveal Dock4 as a candidate pathogenic gene on chromosome 7q.
Zhou L; Opalinska J; Sohal D; Yu Y; Mo Y; Bhagat T; Abdel-Wahab O; Fazzari M; Figueroa M; Alencar C; Zhang J; Kambhampati S; Parmar S; Nischal S; Hueck C; Suzuki M; Freidman E; Pellagatti A; Boultwood J; Steidl U; Sauthararajah Y; Yajnik V; McMahon C; Gore SD; Platanias LC; Levine R; Melnick A; Wickrema A; Greally JM; Verma A
J Biol Chem; 2011 Jul; 286(28):25211-23. PubMed ID: 21532034
[TBL] [Abstract][Full Text] [Related]
33. Prognostic significance of TET2 mutations in myelodysplastic syndromes: A meta-analysis.
Guo Z; Zhang SK; Zou Z; Fan RH; Lyu XD
Leuk Res; 2017 Jul; 58():102-107. PubMed ID: 28521175
[TBL] [Abstract][Full Text] [Related]
34. Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2.
Ko M; Huang Y; Jankowska AM; Pape UJ; Tahiliani M; Bandukwala HS; An J; Lamperti ED; Koh KP; Ganetzky R; Liu XS; Aravind L; Agarwal S; Maciejewski JP; Rao A
Nature; 2010 Dec; 468(7325):839-43. PubMed ID: 21057493
[TBL] [Abstract][Full Text] [Related]
35. Genetic predisposition syndromes: when should they be considered in the work-up of MDS?
Babushok DV; Bessler M
Best Pract Res Clin Haematol; 2015 Mar; 28(1):55-68. PubMed ID: 25659730
[TBL] [Abstract][Full Text] [Related]
36. A genetic development route analysis on MDS subset carrying initial epigenetic gene mutations.
Li X; Xu F; Wu LY; Zhao YS; Guo J; He Q; Zhang Z; Chang CK; Wu D
Sci Rep; 2020 Jan; 10(1):826. PubMed ID: 31964915
[TBL] [Abstract][Full Text] [Related]
37. Prognostic classification and risk assessment in myelodysplastic syndromes.
Cazzola M; Malcovati L
Hematol Oncol Clin North Am; 2010 Apr; 24(2):459-68. PubMed ID: 20359637
[TBL] [Abstract][Full Text] [Related]
38. Molecular Testing in Patients with Suspected Myelodysplastic Syndromes.
Moyo TK; Savona MR
Curr Hematol Malig Rep; 2016 Dec; 11(6):441-448. PubMed ID: 27734261
[TBL] [Abstract][Full Text] [Related]
39. Molecular bases of myelodysplastic syndromes: lessons from animal models.
Komeno Y; Kitaura J; Kitamura T
J Cell Physiol; 2009 Jun; 219(3):529-34. PubMed ID: 19259975
[TBL] [Abstract][Full Text] [Related]
40. Cryptic aberrations may allow more accurate prognostic classification of patients with myelodysplastic syndromes and clonal evolution.
Svobodova K; Lhotska H; Hodanova L; Pavlistova L; Vesela D; Belickova M; Vesela J; Brezinova J; Sarova I; Izakova S; Lizcova L; Siskova M; Jonasova A; Cermak J; Michalova K; Zemanova Z
Genes Chromosomes Cancer; 2020 Jul; 59(7):396-405. PubMed ID: 32170980
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
